Amphastar Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price
Amphastar Pharmaceuticals, Inc. (AMPH) had Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price of $11.95 per share as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue · last filed 2026-08-06
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price $11.95.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price $12.11.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price $15.73.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price $15.75.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price |
|---|---|
| 2026-06-30 | $11.95 10-Q · filed 2026-08-06 |
| 2026-03-31 | $12.11 10-Q · filed 2026-05-07 |
| 2025-12-31 | $15.73 10-Q · filed 2026-08-06 |
| 2025-09-30 | $15.75 10-Q · filed 2025-11-06 |
| 2025-06-30 | $15.77 10-Q · filed 2025-08-07 |
| 2025-03-31 | $15.99 10-Q · filed 2025-05-08 |
| 2024-12-31 | $16.76 10-K · filed 2026-02-26 |
| 2024-09-30 | $16.76 10-Q · filed 2024-11-07 |
| 2024-06-30 | $16.70 10-Q · filed 2024-08-09 |
| 2024-03-31 | $16.54 10-Q · filed 2024-05-10 |
| 2023-12-31 | $12.68 10-K · filed 2025-03-03 |
| 2023-09-30 | $12.68 10-Q · filed 2023-11-08 |
| 2023-06-30 | $12.64 10-Q · filed 2023-08-09 |
| 2023-03-31 | $12.39 10-Q · filed 2023-05-09 |
| 2022-12-31 | $9.48 10-K · filed 2024-02-29 |
| 2022-09-30 | $9.48 10-Q · filed 2022-11-08 |
| 2022-06-30 | $9.47 10-Q · filed 2022-08-09 |
| 2022-03-31 | $9.22 10-Q · filed 2022-05-10 |
| 2021-12-31 | $6.95 10-K · filed 2023-03-01 |
| 2021-09-30 | $6.96 10-Q · filed 2021-11-09 |
| 2021-06-30 | $6.95 10-Q · filed 2021-08-09 |
| 2021-03-31 | $6.96 10-Q · filed 2021-05-07 |
| 2020-12-31 | $6.50 10-K · filed 2022-03-11 |
| 2020-09-30 | $6.50 10-Q · filed 2020-11-06 |
| 2020-06-30 | $6.50 10-Q · filed 2020-08-07 |
| 2020-03-31 | $6.52 10-Q · filed 2020-05-11 |
| 2019-12-31 | $6.99 10-K · filed 2021-03-15 |
| 2019-09-30 | $6.99 10-Q · filed 2019-11-08 |
| 2019-06-30 | $6.97 10-Q · filed 2019-08-09 |
| 2019-03-31 | $6.91 10-Q · filed 2019-05-10 |
| 2018-12-31 | $5.47 10-K · filed 2020-03-16 |
| 2018-09-30 | $5.47 10-Q · filed 2018-11-09 |
| 2018-06-30 | $5.47 10-Q · filed 2018-08-09 |
| 2018-03-31 | $5.41 10-Q · filed 2018-05-10 |
| 2017-12-31 | $4.21 10-K · filed 2019-03-15 |
| 2017-09-30 | $4.21 10-Q · filed 2017-11-09 |
| 2017-06-30 | $4.17 10-Q · filed 2017-08-09 |
| 2017-03-31 | $4.16 10-Q · filed 2017-05-10 |
| 2016-12-31 | $3.61 10-K · filed 2018-03-14 |
| 2016-09-30 | $3.63 10-Q · filed 2016-11-09 |
| 2016-06-30 | $3.39 10-Q · filed 2016-08-09 |
| 2016-03-31 | $3.42 10-Q · filed 2016-05-10 |
| 2015-12-31 | $3.44 10-K · filed 2017-03-15 |
| 2015-09-30 | $3.49 10-Q · filed 2015-11-13 |
| 2015-06-30 | $3.30 10-Q · filed 2015-08-13 |
| 2015-03-31 | $3.39 10-Q · filed 2015-05-14 |
| 2014-12-31 | $3.34 10-K · filed 2016-03-15 |
| 2014-09-30 | $3.39 10-Q · filed 2014-11-13 |
| 2014-06-30 | $3.29 10-Q · filed 2014-08-13 |
| 2013-12-31 | $3.12 10-K · filed 2016-03-15 |
| 2012-12-31 | $4.01 10-K · filed 2015-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |